Antipsychotics in the Treatment of Autism by Gottfried, Carmem & Riesgo, Rudimar
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Antipsychotics in the Treatment of Autism 
Carmem Gottfried1,2 and Rudimar Riesgo1,2 
1Neuroglial Plasticity Laboratory at Department of Biochemistry, 
Postgraduate Program of Biochemistry, Institute of Basic Health Sciences, 
 2Translational Research Group in ASD (GETEA), 
Child Neurology Unit, Clinical Hospital of Porto Alegre, 
1,2Federal University of Rio Grande do Sul, Porto Alegre, RS, 
Brazil 
1. Introduction 
The neurobehavioral syndromes are more frequent than we usually think. They are clinical 
challenges, because they demand knowledge from the physician as well as time for the 
correct approach. Such complaints are very frequent in hospital and addition to the private 
practice. For example, according to a survey carried out in our Hospital, the Child 
Neurology Unit made 10,622 evaluations in 2010, most of which were neurobehavioral 
syndromes including autism and other Pervasive Development Disorders. 
Because of the subtlety of the boundaries between Neurology and Psychiatry, the term 
neurobehavioral could also be called neuropsychiatric. These boundaries have been 
explored both in the clinical (Nunes and Mercadante, 2004) and in the experimental area 
(Quincozes-Santos et al., 2010). It is important to build a bridge between the clinical and the 
experimental research, especially when the issue is neuropsychiatric disorders. This linkage 
indubitably enhances the common knowledge of neurobehavioral alterations as well as it 
promotes the reciprocal enthusiasm.  
One of the most intriguing neurobehavioral syndromes is autism. The challenge starts with 
the difficulty of defining the disorder, continues with the limitations imposed by the lack of 
a clinical marker, and ends with the difficulties in the experimental research field.  
The word autism was used for the first time by the Swiss psychiatrist Eugen Bleuler in 1911. 
“Autism” came from the Greek word "autos," meaning self. However, the landmark paper 
describing autism came from the Austrian psychiatrist Leo Kanner, who described eleven 
children that shared common behavior, with a peculiar inability to establish affective and 
interpersonal contact. He published the paper “Autistic disturbances of affective contact” in 
the Journal Nervous Child (Kanner, 1943).  
In 1944, the Austrian pediatrician Hans Asperger described cases of children with some 
behavioral characteristics that resembled those of children with autism, but with a peculiar 
type of language as well as normal cognitive performance (Gadia et al., 2004). He published 
an article in German in 1944 entitled “Die ‘Autistischen Psychopathen’ im Kindesalter” in 
Archiv fur Psychiatrie und Nervenkrankheiten that was translated into English only in 1989.  
To date, more than half a century since Kanner´s study, the number of papers in PubMed 
containing the word autism has risen above 17,000. From this total, the percentage of 
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published papers comprising different keywords correlated to autism (see Figure 1), reveals 
that the most frequent words in a set of selected targets were developmental, brain and 
psychiatry. Curiously, the word environment occurs in only 5% of papers. It was a surprise, 
considering evidence indicating that environment plays a role in the development of autism 
(Landrigan, 2010). In fact, the prevalence of autism is higher than previously thought and if 
it is rising, the rise might be associated with a shift in the environment. Further, the 
appearance of keywords related to glial cells (astrocyte, oligodendrocytes and microglia) can be 
noted, and, as expected, in less than 2% of papers indicating an emerging and promising 
field of investigation on ASD. 
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Fig. 1. Number of papers published in PubMed. Values were obtained combining the word 
“autism” with selected keywords related to ASD and neural studies. Number in parenthesis 
indicates the first year of publication in PubMed of each word combination. Keyword 
autism = 100% = 17,199 papers.  E.g. autism + developmental = 23%, with the first paper 
with this combination having been published in 1966. Data was obtained in March 23, 2011.  
According to the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition 
criteria, there are five clinical situations that could be encompassed by the term “PDD” 
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(Pervasive Developmental Disorders) or “ASD” (Autism Spectrum Disorders) with the same 
meaning of PDD or autism. The terms PDD or ASD are interchangeable and they are widely 
used in clinical practice to refer to children with autism or any other of the related disorders 
(Gadia et al., 2004). Actually, the terms PDD and ASD are not a specific diagnosis, but a kind 
of umbrella with five different diagnostic categories based on clinical findings. 
The five clinical ASD diagnoses admitted by DSM-IV-TR (APA, 2002) are: a) Autistic 
Disorder; b) Asperger Disorder; c) Rett Disorder; d) Childhood Disintegrative Disorder; e) 
PDD-NOS (Pervasive Developmental Disorder – Not Otherwise Specified).  
In terms of frequency, our group found that the most prevalent ASD is the PDD-NOS, 
followed by Autistic Disorder, and then by Asperger Disorder. Rett’s Disorder and 
Childhood Disintegrative Disorder are seen less frequently in the clinical practice (Longo et 
al., 2009).   
One of the major challenges of cognitive neuroscience is to understand how changes in the 
structural properties of the brain affect the plasticity exhibited whenever a person develops, 
ages, learns a new skill, or adapts to a neuropathology (Keller and Just, 2009). There are 
many hypotheses in this field attempting to explain the genetics, neurotransmitter 
imbalances, early childhood immunizations, xenobiotic and teratogenic agents, and 
maternal infection (Buehler, 2011).  
With the advent of electroencephalography, the aberrant patterns observed in patients with 
autism have contributed to the contemporary understanding of the syndrome as a brain-
based disorder. There is a positive correlation between increasing radiate white matter 
volume and motor skill impairment in children with autism (Mostofsky et al., 2007). 
Moreover, macrocephaly is observed in 15-35% of patients with autism (Bailey et al., 2008).  
The clinical onset of autism appears to be preceded by two phases of brain growth 
abnormalities: a reduced head size at birth, followed by sudden and excessive increase 
between 1–2 months and 6–14 months of age (Pardo and Eberhart, 2007), which may reflect 
a disruption of multiple fundamental processes during the patterning and organization of a 
cortical cytoarchitecture. The effects of these disrupted processes may be manifested widely, 
with atypical or adaptive behaviors associated with these changes.  
Considering that the etiology of autism still unknown and that there are no effective medical 
treatments that address the core symptoms of ASD concerning communication, inappropriate 
social interactions and restricted interests or behaviors, the promise of future medical 
treatments for ASD is through the identification of the underlying pathophysiological 
mechanisms, and treatment of these molecular and cellular deficits (Coury, 2010).  
The psychopharmacotherapy used in autism is generally addressed to behavioral 
symptoms, such as: anxiety, lack of attention, irritability, hyperactivity, humor oscillations, 
sleep disturbances, aggressiveness and self-injury. Another clinical problem in ASD is 
epilepsy, reaching up to twenty times more frequency in autism. Even though, many of the 
above mentioned behavioral symptoms could be reduced after treatment; the antipsychotic 
drugs can adversely facilitate epilepsy.  
Nevertheless, the antipsychotic treatment in ASD has expanded, sometimes accompanied by 
several clinical and metabolic side-effects of primary concern (weight gain, hyperglycemia 
and dyslipidemia), especially by the greater risk within the pediatric population.  
In this context, the present chapter aimed to review (i) the neurotransmitter dysfunctions in 
ASD and the most commonly prescribed antipsychotics; (ii) the vantages and advantages 
regarding to the antipsychotics side effects and (iii) the non-neuronal possible targets of 
atypical antipsychotics in brain.  
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2. Ligand-receptor dysfunctions in autism 
The wide diversity of core characteristics of ASD and the variety of comorbidities makes the 
diagnostic procedure and clinical management of the patient more difficult. In the immature 
brain, the neuronal migration and emplacement are modulated paracrinally by 
neurotransmitters and their receptors (Manent and Represa, 2007). The complex functions 
being related to neurotransmitters during brain development indicates that these molecules 
can play central roles in a wide variety of neurobiological alterations associated with ASD. 
Likewise, the multifactorial basis of ASD is engineered by complex developmental changes 
in the brain that occur during the first few years of life. These changes include alterations (a) 
at the anatomical level, in the limbic system (hippocampus and amygdala), cerebellum, 
cortex, basal ganglia and brainstem (Bauman and Kemper, 2005) and (b) at the 
neurochemical level, in a number of key ligand-receptor systems, including serotonergic, 
dopaminergic, noradrenergic, cholinergic, opioid, amino acids and hormone mechanisms 
(Lam et al., 2006). Full understanding of these systems in the brain involves different areas of 
knowledge such as genomics, neurochemistry, electrophysiology, and behavior. 
2.1 Most prevalent neurotransmitter/receptor dysfunctions in ASD 
2.1.1 Serotonergic system 
The neurotransmitter serotonin is synthesized from the essential aminoacid tryptophan. 
Firstly, tryptophan is hydroxylated (by tryptophan hydroxylase) into 5-hydroxytryptophan, 
which is then decarboxylated (by aromatic L-amino acid decarboxylase) resulting in 
serotonin or 5-hydroxytryptamine (5-HT).  
Serotonin has been linked to a wide variety of behaviors including those having to do with 
feeding and body-weight regulation, social hierarchies, aggression and suicidal behavior, 
obsessive compulsive disorder, alcoholism, anxiety, and affective disorders. This 
neurotransmitter plays two important roles in the mammalian brain: it regulates 
serotonergic outgrowth and maturation of the target regions in the developing brain 
(Whitaker-Azmitia, 2005), and modulates the function and plasticity of the adult brain 
(Catalano, 2001).   
The function of serotonin in ASD has been has been investigated by means of biomarker, 
neuroimaging and genetic approaches (Scott and Deneris, 2005). An important investigation 
by positron emission tomography (PET) shows that the normal brain developmental peak of 
5-HT synthesis cannot be observed in children with autism (Chandana et al., 2005; Chugani 
et al., 1999).  
5-HT has been shown to reside in platelets and is best measured in a whole blood assay. 
One of the most consistent biological findings related to autism is elevated whole blood 5-
HT levels found in about 1/3 of cases, which may be connected to cellular immune 
abnormalities found in autism, as 5-HT display immunoregulatory effects primarily via 5-
HT1A, 5-HT2 and 5-HT3 receptors located on lymphocytes and monocytes/macrophages 
(Burgess et al., 2006). Besides hyperserotonemia, the binding of 5-HT2 receptors seems to be 
decreased in platelets or whole blood (Cook et al., 1993) and in the cerebral cortex of 
individuals with autism (Murphy et al., 2006).  
Polymorphisms in the promoter region of the serotonin transporter gene SLC6A4 have also 
been reported to be associated with autism and cortical gray matter volume (Pardo and 
Eberhart, 2007). The gene ITGB3 has been suggested as a regulator of serotonin levels in 
autism based on genetic association studies (Weiss et al., 2006).  
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2.1.2 Dopaminergic system 
Dopamine (DA) is a catecholamine synthesized from the essential amino acid tyrosine. Once 
ingested, tyrosine is hydroxylated (by tyrosine hydroxylase) into L-dihydroxyphenylalanine 
(L-DOPA), which is then converted into dopamine via the enzyme DOPA decarboxylase.  
Most DA-containing neurons lie in the midbrain. In particular, three important DA systems 
project from the substantia nigra and the ventral tegmental area. The dopaminergic system 
modulates a wide range of behaviors and functions, including cognition, motor function, 
brain-stimulation reward mechanisms, eating and drinking behaviors, sexual behavior, 
neuroendocrine regulation, and selective attention (Lam et al., 2006).  
The role of DA in autism begins with the observation that some DA blockers (i.e., 
antipsychotics), appear to be effective in treating some aspects of autism. Specifically, the 
antipsychotics supposedly to decrease hyperactivity, stereotypies, aggression, and self-
injury (Young et al., 1982). In addition, animal research has shown that stereotypies and 
hyperactivity can be induced by increasing dopaminergic functioning. These observations 
suggested that dopaminergic neurons could be overactive in autism, which led to studies of 
DA function. These studies have been performed using several methods, including blood 
and urine measurements of DA and its major metabolite, and measurements of this 
metabolite in CSF (Lam et al., 2006). 
The investigations of DA transporter binding have shown a significant and local increase of 
function in the medial region of the orbitofrontal cortex in patients with autism (Nakamura 
et al., 2010). PET studies showed increased striatal dopamine D2 receptor binding in children 
with autism confirming the over functioning in the dopaminergic system (Fernell et al., 
1997). Also, there are evidences pointing increased dopamine synthesis and storage in the 
striatum and frontal cortex of adults with Asperger syndrome (Nieminen-von Wendt et al., 
2004). The orbitofrontal cortex is a key structure in the network underlying emotional 
regulation. Dysfunction in the orbitofrontal-limbic circuit may be associated with behaviors 
in autism, such as impulsivity, difficulties in changing the focus of interest and aggressive 
behavior (Nakamura et al., 2010).  
2.1.3 Cholinergic system 
Acetylcholine (ACh) is a simple molecule synthesized from choline and acetyl-CoA through 
the action of choline acetyltransferase and is the neurotransmitter found at the neuromuscular 
junction, in the autonomic nervous system ganglia and at multiple sites in the CNS (Fagerlund 
and Eriksson, 2009). There are two kinds of ACh receptors: nicotinic and muscarinic. Both are 
found in the brain, although muscarinic receptors are more prevalent.   
The role of acetylcholine in ASD has been investigated due to neuropathological deficits 
found in cholinergic neurons located in the basal forebrain of individuals with autism 
(Bauman & Kemper, 1994), suggesting that a disruption in this system could be linked to the 
cognitive deficits that often accompany autism (e.g., problems with attention, learning) 
(Lam et al., 2006).  
2.1.4 Catecholaminergic system 
Noradrenaline (NA) is a catecholamine that is synthesized from DA through the action of 
the enzyme DA beta-hydroxylase. Nearly every region of the brain receives input from 
noradrenergic neurons (Lam et al., 2006). The neuronal projections from locus coeruleus are 
distributed widely throughout the brain, and play a critical role in attention, filtering of 
irrelevant stimuli, stress response, anxiety, and memory (Harris and Fitzgerald, 1991).  
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Since many of these functions are impaired in individuals with autism, researchers have 
investigated whether noradrenergic system shows alterations. Recent studies of people with 
autism have demonstrated variants at two polymorphic sites of the β2-adrenergic receptor 
(ADRB2) leading to increased activity which could result in increased risk of autism 
(Cheslack-Postava et al., 2007).  
Noradrenergic activity has been assessed in autism via the measurement of NA and its 
central and/or peripheral metabolites in the blood, urine, and CSF. Noradrenergic function 
can be measured in the blood as NA itself, and as its principal central metabolite, 3-
methoxy-4-hydroxyphenylglycol (MHPG). Unlike some of the other neurotransmitter 
systems, central and peripheral noradrenergic systems are tightly coupled with blood and 
CSF concentrations being highly correlated (Lam et al., 2006).   
2.1.5 Opioid system 
Opioid receptors are G protein–coupled receptors, characterized by 7 transmembrane 
domains, and are located in the periphery and in all areas of the CNS. These receptors are 
known to be involved in integrating information about pain in the following areas: the 
brainstem, the medial thalamus, the spinal cord, the hypothalamus, and the limbic system. 
They are termed µ (mu), κ (kappa), and δ (delta) receptors. Morphine is considered the 
prototypical µ-agonist. 
There is an “opioid hypothesis” suggesting that childhood autism may result from excessive 
brain opioid activity during the neonatal period which may constitutionally inhibit social 
motivation, yielding autistic isolation and aloofness (Sahley and Panksepp, 1987). 
Interestingly, some children with autism seem to feel less pain when compared with 
typically developed children. The hypothesis of excessive brain opioid activity is based on a 
similarity between autistic symptomatology and abnormal behavior induced in young 
animals by injections of exogenous opioids and the therapeutic effects of the long lasting 
opioid receptor blocking agent naltrexone in autism. Naltrexone is a Food and Drug 
Administration (FDA)-approved drug used as an opiate antagonist for treating opiate drug 
and alcohol addiction since the 1970’s. It is a competitive antagonist of opioid receptors 
OPRM1, OPRD1 and OPRK1 and was used in children with autism in cases of hyperactivity 
(Desjardins et al., 2009). 
2.1.6 Aminoacid-neurotransmitter system 
The activation of specific GABA and glutamate receptors during cell migration is necessary 
to the regulation of radial and tangential migrations (Manent and Represa, 2007) and an 
imbalance in this system can be involved in several brain pathologies. There is increasing 
evidence to suggesting a role for the opioid system in the control of pathophysiology of 
neurological disorders (Alzheimer's, Parkinson's, and Huntington's diseases, spinal cord 
injury, epilepsy, hypoxia, and autism) (Nandhu et al., 2010).  
Recent studies have pointed to abnormalities in glutamate and GABA neurotransmission in 
ASD, e.g. mutations in glutamate receptor genes GRIN2A and GRIK2 and multiple GABA 
receptor genes (Webb, 2010). Therefore, additional studies are necessary to better 
understand glutamate metabolism in ASD.  
From the translational point of view, the fact that ASD patients are up to twenty times more 
prone to have epilepsy, added to the abovementioned information, can let us suppose that 
the possible relationship between autism and epilepsy can be explained, at least in part, as a 
consequence from the imbalance between GABA and glutamate functioning. 
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2.1.7 Hormone-melatonin system 
The discovery of melatonin in 1958 (Alberti, 1958) heralded a new field of research in 
reproductive physiology. Melatonin is produced in the dark by the pineal gland and is a key 
regulator of circadian and seasonal rhythms. A low melatonin level has been reported in 
individuals with ASD caused by a primary deficit in N-acetylserotonin O-methyltransferase 
(ASMT) (Melke et al., 2008), an enzyme that catalyzes the final reaction in melatonin 
biosynthesis.  
Melatonin is metabolized to 6-hydroxy-melatonine in the liver and the main metabolite 
excreted is 6-sulphatoxy-melatonine. Isolated measurements of melatonin are difficult to 
interpret given its circadian secretion. However urinary excretion of 6-sulphatoxy-
melatonine may be helpful in studying pineal function. 
3. Behavioral symptoms and psychopharmacotherapy on ASD 
The qualitative deficits in the social interaction of children with autism may manifest 
themselves as social isolation and/or inappropriate social behavior characterized by poor 
eye contact, a difficulty to participate in group activities, affective indifference or 
inappropriate manifestation of affection or a lack of social or emotional empathy (Gadia et 
al., 2004). Children with Asperger disorder may also possibly not have any kind of problems 
in eye contact, but they may have some social inadequacy, particularly due to their 
difficulties with understanding the metaphors, the jokes and some social rules and 
behaviors. There is no available drug for improving the social abilities of ASD patients 
(Rotta and Riesgo, 2005). 
The difficulties in communication occur in varying degrees in verbal as well as the non 
verbal ability to share information. Some children do not develop any kind of 
communication skills. Others speak an immature language characterized by abnormal 
prosody, inappropriate intonation, jargon, echolalia, the reversal of pronoun, etc. Those who 
maintain adequate capacity of expression may have the inability to initiate or continue a 
conversation appropriately. On the other hand, children with Asperger disorder may not 
have clear difficulties in communication. Their language may actually be characterized by a 
particularly correct speech. There is no available drug designed for improving the capacity 
of communication capacity in ASD patients. The best treatment for this problem is provided 
by speech therapy (Rotta and Riesgo, 2005). 
The repetitive and stereotyped patterns of behavior, characteristic of autism include 
resistance to any sort of changes, the insistence on certain routines, the excessive attachment 
to objects and the fascination with the movement of parts, such as wheels or propellers.  
Children with autism may be more interested in objects rather than people. Although some 
children seem to play, they may be more concerned in aligning, handle or throw away toys 
than use them into their symbolic purpose. The motor and verbal stereotyped pattern of 
behavior may also be observed in certain activities such as clapping hands repeatedly, 
circling, repeating certain words, phrases, jingles or even complete songs. If these 
stereotyped and repetitive patterns of behavior are part of an anxiety disorder, maybe they 
can ameliorate with anti-anxiety medications (Gadia et al., 2004). 
From the clinical point of view, some of these above mentioned behavioral symptoms may 
also occur in children with mental disability without autism, and this is a recurrent problem. 
Additionally, patient with autism may have varied degrees of mental disability ranging 
from no impact in the cognitive performance, that may occur in Asperger disorder, to the 
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opposite side of the spectrum, characterized by of moderate mental disability that usually 
occur in the classic form of autism. This overlay of diagnostics, autism versus mental 
disability, albeit sometimes partial, can create difficulties to clinicians.  
Fortunately, there are some clinical instruments that could help in distinguishing between 
autism and mental disability without autism, such as the Autism Screening Questionnaire 
(ASQ). The ASQ is useful both in the clinical practice as well as from the research point of 
view and its translation and validation is already available for different languages and 
countries (Sato et al., 2009). 
During routine clinical practice, the ideal situation would be to add the DSM-IV-TR (APA, 
2002) criteria with the so-called “handmade diagnosis”, which means the personal 
experience prudently combined with the officially adopted parameters. Once the diagnosis 
is confirmed, there is inaccuracy in measuring the autism behavior symptom’s intensity. For 
sure, it could be easier to establish, from the clinical point of view, when compared and 
interconnected with the research approach. 
Frequency and intensity of behavioral and psychological symptoms could be easily accessed 
by the physician through his making use of previous experience. However,, the same 
symptoms rating could be somewhat more difficult from the research perspective. One of 
the most useful clinical instruments for this purpose is the CARS (Childhood Autism Rating 
Scale), that already was translated and validated in several languages and countries (Pereira 
et al., 2008). 
In addition to the DSM-IV-TR criteria, there are other clinical findings that are frequently 
observed. These findings are not listed in the commonly used guidelines for autism 
diagnosis. For example, children with autism may have hypersensitivity to certain sounds 
or noises, such as a kitchen mixer, a jackhammer or fireworks. These noises can be extremely 
uncomfortable, leading children to covering ears with their hands and sometimes to 
screaming (Gomes et al., 2004). Other findings not listed in the official autism criteria of 
autism includes: a) children with autism may keep walking on his toes for more time when 
compared with children with typical development; b) children with autism may have a 
higher pain threshold in comparison with people with typical development; c) children with 
autism may feel uncomfortable with the usual pediatric clinical maneuvers, such as 
touching or auscultation procedures; d) patients with autism may demonstrate a fear for 
people approaching, etc.   
Sleep disorders can be identified in young children with ASD, occasionally even before the 
diagnosis confirmation. This symptom can be devastating to parents due its intensity. The 
mean age of ASD patients with sleep disorders is usually between one and three years of 
age, but disorders may also be identified earlier. From the research perspective, sleep 
disorders in these patients could be one interesting field.  Sleep disorders, if not improving 
response to a non-medical approach, may be treated with Melatonin or with 
benzodiazepines.  
Usually, one of the first behavioral symptoms in patients with ASD is language delay. In 
this case, it is mandatory to rule out hearing impairment before autism is diagnosed. In this 
group of patients, a normal global development it is not uncommon until about 18 or 24 
months of age, followed by loss of language and social interaction. This diminution in social 
and communications skills may begin with poor eye contact, followed by a clear disinterest 
in people as opposed to objects. In this sense, it is important to monitor the development of 
these skills in children that show autistic symptoms, especially throughout the period when 
a child is between one and three years of age (Rotta and Riesgo, 2005). 
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When it comes to cerebral hemispheres specialization during childhood, language seems to 
be one of the most powerful inducers. In addition, language can also be useful in 
differentiating between autism and Asperger disorder. By definition, language can be 
unremarkable in Asperger’s patients, while language is usually absent in the severe forms of 
autism. Actually, patients with Asperger have preserved both language and cognition, 
especially the latter. Sometimes, patients with Asperger present a peculiar type of pedantic 
and extremely correct language, leading the parents of these children to be proud of their 
adult-like type of expressive language (Rotta and Riesgo, 2005).  
In certain cases, clinicians may have difficulties with distinguishing between these two 
diagnostics as the following questions arise. Is this a case of “high functioning autism” or an 
Asperger disease? Actually, from the clinical perspective, it is sometimes impossible to 
differentiate between these situations. However, it is somewhat easier to differentiate the 
pure form or autism from Asperger disease. In the clinical practice a simple rule exists 
which states that children with autism usually “live in their own world”. By the other side, 
patients with Asperger in general “live in our world in their own way”.  
In terms of clinical diagnosis, to date we have no biological marker. Consequently, previous 
clinical experience is needed in order to assure a safe approach. Furthermore, some patients 
may have so many associated behavioral alterations that the core diagnosis, as for example 
ASD, could be delayed or may not even be taken into consideration. 
For instance, some children´s behavior may show up to five alterations associated with ASD. 
The initial clinical diagnosis may be ADHD (Attention-Deficit/Hyperactive Disorder), 
and/or Bipolar Disorder, Anxiety Disorder, Depressive Disorder, Tics Disorder, etc. During 
the follow-up inevitably it will be clear that the principal diagnosis is actually ASD, and all 
the other diagnostics are just ASD associated features.  
From the clinical perspective, one of the most prevalent behavioral symptoms is the pure 
form of hyperactivity, especially in the mentally disabled patients. It must be kept in mind 
that any type of environmental change can provoke this specific symptom and/or can 
deteriorate other associated behavioral manifestations. The approach of agitation can 
include both behavioral and/or psychopharmacological treatment. In these cases, when 
patient are extremely agitated and/or disorganized, the use of antipsychotics is one of the 
best choices. Unfortunately, there is a paucity of evidence-based studies of the efficacy of the 
antipsychotic drugs in treating autism. 
The co-occurrence of ADHD and ASD is no rarity and, from the psychopharmacological 
perspective, it is crucial to define which one of the two is the principal cause of impairment, 
because the wrong choice of medication can deteriorate the patient’s behavior. For example, 
stimulants drugs can provoke an increase in hyperactivity in ASD patients with concomitant 
ADHD. Long action stimulants in particular may have this effect. 
In the clinical practice, at present, risperidone and aripoprazole are the better choice to ASD 
associated agitation. This, antipsychotic drugs are already approved by FDA for the 
treatment of childhood autism. Other medications related to the psychopharmacotherapy in 
ASD are described in Table 1. Initially, the main dosage of risperidone was considerably 
high, reaching up to 6mg/day. Today, clinicians are aware that, if there is no response to 
3mg/day, probably no benefit will be obtained with higher doses of risperidone. 
Further, in clinical practice, coincidently this specific daily dose regimen of 3mg/day of 
risperidone seems to be the threshold dose for inducing seizure in susceptible children. In 
Child Neurology, we frequently have to deal with patients with epilepsy. The mean 
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prevalence of epilepsy in non-autistic children is about 1%. In comparison, the mean 
prevalence of epilepsy in children with ASD children reaches 20%, a rate that is clearly of 
both clinical and statistical significance. The possible relationship between ASD and 
epilepsy is one of the coming and intriguing challenges to be studied. This relationship is 
one of the “state of art” issues in autism, both from the clinical point of view as well as from 
the research perspective. 
A further frequent symptom of behavior in clinical practice with ASD patients is the 
instability of the baseline mood. Children’s mood normally changes faster than with adults’ 
mood. Increasing our knowledge of mood regulation in childhood specifically, it is 
important to remember that mood changes in ASD patients occur more rapidly when 
compared with typically developed children. This kind of symptom may occur both in the 
mentally disabled and in the Asperger group of patients. If one ASD patient also has 
epilepsy, the addition of sodium divalproate can both protect against seizures and at the 
same time improve the mood control. Dealing with patients with a refractory humor 
deregulation is not unlikely. The use of lithium still is the best choice in some cases of severe 
mood oscillations.  
Although not being an unchangeable rule, from the clinical point of view, the intensity of 
behavioral symptoms is clearly related to both with gender and cognition. The usual 
observation is that behavioral symptoms are more prominent in girls than in boys with 
autism. Additionally, we frequently see that the intensity of these symptoms is inversely 
related to cognition.  
One of the principal prognostic factors in the clinical approach is cognition. In this sense, the 
main problem is how to evaluate the cognition in non-verbal ASD patients. Our group is 
now conducting a research in order to find the most useful clinical tool to evaluate cognition 
in non-verbal ASD patients. One of the possibilities is to attempt to use the same 
instruments used in another group of patients, such as those children without autism who 
are candidates to auditory prosthesis.  
From the clinical perspective, feeding problems are frequently identified. Usually ASD 
patients have difficulties with changing their alimentation. For example, they are capable of 
repeating the same menu week after week without any complaint. Weight gain can also 
occur in autism, and sometimes it is difficult to identify its etiology. It can be a result of a 
stereotyped and exaggerated consumption and/or it can also be a consequence of the use of 
antipsychotic drugs. Further, children with autism may present several types of food 
allergy. 
Additional useful clinical information could be how different behavioral symptoms change 
during the lifetime of ASD patients. First of all, obviously there is an ontogenetic evolution 
of each one of the behavioral manifestations in normally developed children. In other 
words, it is crucial to know how behavior can normally change during childhood 
neuropsychological development. For instance, hyperactivity would be a “normal” finding 
until children reach the age of five years because of the normal brain maturation that occurs 
from the occipital lobe towards to the frontal cerebral lobe.  
In terms of gender versus behavior, usually hyperactivity is more prevalent in normal boys 
when compared with normal girls. Humor control, language skills and social competence 
usually improve in normally developed children as time passes. Normal girls tend to 
improve faster their language skills and their social competence when compared with 
normal boys. 
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Selected primary 
publications 
First publication in 
ASD 
Clinical information 
Psychostimulants   Used in child neurology and 
psychiatry to treat attention 
deficit disorder, narcolepsy, 
and some forms of refractory 
depression, when used 
combined with 
antidepressants  
 Methylphenidate (Barison and 
Massignan, 1956) 
(Hoshino et al., 1977) 
 Pemoline (Lucas and 
Knowles, 1963) 
(King et al., 1993) 
 Buspirone (Goldberg, 1979) (Realmuto et al., 1989) 
Antidepressants-
tricyclic 
  
Indicated to treat depression 
and/or associated anxiety. 
Imipramine may be also 
useful to treat nocturnal 
enuresis and/or associated 
sleep disorder 
 Imipramine (Lehmann et al., 
1958) 
(Campbell et al., 1971) 
 Clomipramine (Volmat et al., 1968) (Brodkin et al., 1997) 
 Desipramine (Olesen, 1963) (Gordon et al., 1992) 
Antidepressants-SSRI   The selective serotonin 
reuptake inhibitors (SSRI), are 
the most commonly 
prescribed antidepressants, 
relatively safe and generally 
cause fewer side effects than 
other types of 
antidepressants. They may be 
also be useful in the whole 
associated spectrum of 
anxiety symptoms   
 Paroxetine (Lassen, 1978) (Posey et al., 1999) 
 Fluoxetine (Fuller et al., 1974) (Mehlinger et al., 
1990) 
 Fluvoxamine (Saletu et al., 1977) (McDougle et al., 
1990) 
 Escitalopram (Hyttel, 1977) (Anderson et al., 2002) Antidepressant drug.  
Antipsychotics (t, typical; a, atypical)  Antipsychotic drugs are used 
to treat psychosis and other 
mental and emotional 
conditions. In ASD they are 
frequently used to treat 
aggressiveness and/or 
agitation. In patients with 
mental disability and ADHD 
(Attention 
Deficit/Hyperactivity 
Disorder) risperidone may be 
more efficient when 
compared with 
methylphenidate 
 Haloperidolt (Divry et al., 1959) (Faretra et al., 1970) 
 Risperidonea (Faretra et al., 1970) (Purdon et al., 1994) 
 Olanzapinea (Fuller and Snoddy, 
1992) 
(Malek-Ahmadi and 
Simonds, 1998) 
 Quetiapinea (Pullen et al., 1992) (Martin et al., 1999) 
 Ziprasidonea (Bench et al., 1993) (Alessi, 2003) 
 Aripiprazolea (Kikuchi et al., 
1995) 
(Rugino and Janvier, 
2005) 
 Clozapinea (Ueki et al., 1970) (Atlas and Gerbino-
Rosen, 1995) 
    
Antiepileptic (anticonvulsant)  There are at least two clinical 
reasons for their use: the 
frequent co-occurrence of 
epilepsy in ASD patients 
and/or the also frequent co-
occurrence of affective 
disorders, especially mood 
disorders.  
 Valproic acid (Lance and 
Anthony, 1975) 
(Sovner, 1989) 
 Carbamazepine (Donner and Frisk, 
1965) 
(Gadow, 1992) 
 Topiramate (Maryanoff et al., 
1987) 
(Pellock, 2004) 
Antiopioid    Naltrexone is an opioid 
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 Naltrexone  (Martin et al., 1973) (Sahley and 
Panksepp, 1987) 
receptor antagonist with 
higher affinity for mu 
receptors than other opioid 
receptor subtypes. 
Nowadays, this drug is not 
used in ASD patients. 
Mood stabilizer    Lithium, discovered in 1817, 
was noticed to have mood 
stabilizing properties in the 
late 1800s. It is an extremely 
useful drug in ASD 
 Lithium  (Andreani, 1957) (Campbell, 1975) 
Hormones    Melatonin is a hormone that 
plays a key role in regulating 
circadian rhythms. Their use 
in treating sleep disorders 
resulted in weaker clinical 
responses than expected. 
 Melatonin  (Alberti, 1958) (Jan and O'Donnell, 
1996) 
Table 1. Psychopharmacotherapy in ASD. Pharmacotherapy options in ASD based upon 
the following target symptom clusters: inattention/hyperactivity, interfering repetitive and 
stereotypic behavior, aggression and self-injurious behavior, humor oscillations, anxiety and 
the core social impairment of autism. 
Analyzing changes in ASD patient’s symptoms during lifetime, it is clear that hyperactivity 
is more prevalent in boys than in girls and it is know that hyperactivity can decrease as time 
passes (Guan et al., 2010). Although aggressiveness itself usually decreases with childhood 
development, we know that the consequences of aggressiveness can worsen with increasing 
age of patients with autism owing to the increase of muscle strength. 
Anxiety can increase in stress situations and also can worsen during their lifetime in patients 
with ASD, especially in children with a less affected cognitive function, like patients with 
Asperger disorder. In this specific group of patients, the most frequent behavioral 
symptoms are depression and/or anxiety. 
As time passes, communication tends to improve in children that are and/or became able to 
communicate. This improve in communication skills is clearly more prominent in the 
patients with Asperger disorder when comparing with other ASD patients.  
The restricted repertoire of activities and interests does not change in intensity as time 
passes, but certainly the types of interests change. Interestingly, the social deficits do not 
improve significantly throughout patient’s lives. 
3.1 Historical landmarks of psychopharmacotherapy  
In 1949, the Australian psychiatrist John Cade showed that lithium calmed maniac 
patients, and Mogens Schou in Denmark confirmed Cade's findings in a double-blind 
study in 1954. About 20 years later, in 1970, the FDA finally approved lithium to treat 
patients with manic-depressive illness. The first publications related to lithium treatment 
and ASD were in 1975.  
The first antipsychotic drug, chlorpromazine, was discovered by the French pharmacologist 
Henri Laborit. In 1944, he noted the antihistamine activity of chlorpromazine, as well as 
other compounds and started to use these drugs in a pharmacological combination to 
prevent surgical shock. However, he curiously observed that chlorpromazine, besides 
www.intechopen.com
 
Antipsychotics in the Treatment of Autism 
 
35 
preventing surgical shock, also induced calmness in patients before the operation. Laborit 
had the bright idea of trying the antipsychotic on schizophrenics and found that it stopped 
their symptoms. In consequence, he had unintentionally discovered the first antipsychotic 
drug. 
In the same year, methylphenidate was synthesized by Ciba chemist Leandro Panizzon, 
who named the compound Ritalin™ because his wife Margherite (nicknamed Rita) used to 
take this drug as a stimulant before playing tennis. 
The first effective pharmacologic treatment for depression was discovered by the clinician 
Roland Kuhn in 1956. This drug was the tricyclic antidepressant imipramine. Kuhn 
published the results of his observations in the Schweizerische Medizinische Wochenschrift 
(Swiss Weekly Medical Journal) in 1957.  Heinz Lehmann, Clinical Director at Douglas 
Hospital, Montreal, Canada, treated depressed with equally good results. Lehmann and two 
co-workers published their results in the Canadian Medical Association Journal in 1958 
(Lehmann et al., 1958).  
The typical antipsychotic drug, haloperidol, was discovered by Paul Janssen and was 
developed in 1957 by the Belgian company Janssen Pharmaceutica. It was approved by the 
by the U.S. Food and Drug Administration (FDA) in April 12, 1967. 
The work which eventually led to the discovery of fluoxetine began at Eli Lilly and 
Company in 1970 with collaboration of Bryan Molloy and Robert Rathbun. After 20 years, 
the first papers related to the fluoxetine treatment of ASD patients were published.   
In 1988, the American psychiatrist John Kane demonstrated that clozapine achieved a good 
response in schizophrenic patients refractory to treatment with other antipsychotic drugs; 
the FDA approves the drug in 1989. 
The atypical antipsychotic risperidone was developed by Janssen-Cilag, first released in 
1994, approved by the FDA in the same year to use in adult psychiatric patients and 
approved for treating ASD only two years later. In the brain, risperidone binds multiple 
neurotransmitter receptors, having a strong affinity to the serotonin 2A (5-HT2A) and 
dopamine D2 receptors, and a good affinity for the -1 and -2C adrenergic receptors and 
for the serotonin receptors 6 and 7 (5-HT6 and 5-HT7). 
4. Antipsychotic side effects in ASD 
The first generation of antipsychotics, today called typical antipsychotics, functions by 
blocking the effects of dopamine, controlling hallucinations and delusions. Because of this 
primary function, this medication is also named neuroleptic which means “seizing the 
neuron”, with high efficiency to some symptoms of autism (lack in social behavior, 
stereotypical behavior) and in behavioral impairments that may be associated with autism 
(aggressive behavior, hyperactivity). However, the use of typical antipsychotics, like 
haloperidol, can induce extrapyramidal side effects, which often lead to persistent tardive 
dyskinesia, limiting the long term use of these drugs.  
Atypical antipsychotics have been prescribed for ASD symptoms as they have lower 
frequency and intensity of side effects compared with the typical one. However, an 
important concern related to the use of atypical antipsychotics is the inducement of 
endocrine and metabolic side-effects (weight gain, obesity, and related metabolic 
abnormalities such as hyperglycemia and dyslipidemia). Obesity is a risk to the 
development of metabolic syndrome and may result in a high-risk state for future 
cardiovascular morbidity and mortality in adult age (Goeb et al., 2010). 
www.intechopen.com
 
Autism Spectrum Disorders – From Genes to Environment 
 
36
The atypical antipsychotics risperidone, olanzapine, quetiapine and ziprazidone are most 
commonly prescribed for ASD. However, only two atypical antipsychotics have been 
approved by the FDA for treating irritability in autistic children. Risperidone was approved 
in late 2006, followed by aripiprazole in 2009.  
5. Non-neuronal targets of Risperidone 
All complex nervous systems consist of two main cell types, neurons and glial cells. In the 
past 20 years evidence has accumulated that supports the existence of bidirectional 
communication between glial cells and neurons (Froes et al., 1999; Gomes et al., 2001). Based 
on this context, it is important to consider that if the functional unit of the brain is not only 
orchestrated by neurons but rather by the neuron-glial complex, consequently must assume 
that both neuronal and glial cells are involved in neural diseases.   
There are three main types of glial cell populations in the CNS, termed astrocytes a diverse 
population of cells with numerous functions; oligodendrocytes, the myelinating cells of the 
CNS (McLaurin and Yong, 1995) and microglia, considered the immune cells of the CNS, 
responding to any kind of pathology with a reaction termed microglial activation (Hanisch 
and Kettenmann, 2007).  
The idea that astrocytes, like neurons, might take up diverse roles in the development and 
function of the CNS has slowly been gaining recognition (Westergaard et al., 1995). 
Nowadays, a considerable amount of evidence has revealed a more active role of astrocytes 
in the physiology of the CNS than previously believed (Araque et al., 2001). It has been 
found that these cells play a crucial role in maintaining normal brain physiology during 
development, releasing molecules important for neuronal survival and dendrite formation. 
Also, astrocytes have been emerging as key modulators of neuronal excitability, synaptic 
transmission (Perea and Araque, 2009) and blood–brain barrier (Wang and Bordey, 2008). 
Common astrocytic reactions that occur in the pathological states are cellular swelling, 
hypertrophy-hyperplasia (astrogliosis) and proliferation (astrocytosis).  
Morphology of astrocytes varies depending on regional localization and shape changes 
potentially may influence neuronal activity and injury via ion channels, neurotransmitter 
receptors and transporters on their processes (Theodosis et al., 2008). In this context, we have 
investigated the effect of risperidone on astroglial cells, evaluating morphology, membrane 
integrity, viability, secretion of S100B, a neurotrophic astrocyte-derived protein and 
glutamate metabolism (glutamate uptake, glutamine synthetase activity and glutathione 
synthesis).  
We demonstrate for the first time that risperidone was able to modulate cell morphology 
and glial adhesion (Quincozes-Santos et al., 2008), contributing to the proposal that glial 
cells also are targets of antipsychotics. In addition, risperidone also increased S100B 
secretion by astroglial cells. S100B is a calcium-binding protein involved in the regulation 
of cytoskeleton and the proliferation of astrocytes. Beyond its intracellular role, S100B, 
depending on its concentration, works as a cytokine for neighboring cells (astrocytes, 
neurons, and microglia) and is able to protect hippocampal neurons against glutamate 
toxicity. Extending these findings to brain plasticity in ASD, it would be possible to 
conceive that risperidone stimulates S100B secretion which in turn can stimulate neuronal 
activity in patients. 
Astrocytes respond to neuronal activity via ion channels, neurotransmitter receptors, and 
transporters on their processes, a plasticity that has important functional consequences since 
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it modifies neurotransmission. We described a significant increase in glutamate uptake and 
in glutamine synthetase (GS) activity by astroglial cells in the presence of risperidone 
(Quincozes-Santos et al., 2010).  
Astrocytes are the only cells in the brain that have the important ability to convert glutamate 
into glutamine via GS. Glutamine, in turn, is taken up by neurons and used for the synthesis 
of glutamate (and then GABA, in GABAergic neurons). However, glutamate has another 
important destination in astrocytes, particularly GSH (glutathione) synthesis (Dringen et al., 
1999). Glutamate serves as a substrate per se for GSH synthesis and as a moiety for exchange 
by cysteine, another substrate for GSH synthesis. Moreover, concomitantly with the increase 
in glutamate uptake and GS activity, an increase in the content of GSH was seen, reinforcing 
the antioxidant activity of astroglial cells mediated by risperidone. In this context, astrocyte 
clearance of glutamate from the synaptic cleft is an important aspect to be considered in 
autism, from both the physiopathologic and the pharmacologic point of view.  
As evidence emerging indicates that signaling between perisynaptic astrocytes and neurons 
at the tripartite synapse display important roles when neural circuits are formed and refined 
(Araque et al., 1999), we propose an integrative model of the tripartite synapse modulated 
by this antipsychotic during treatment in vivo (Figure 2). 
Most studies about pathological abnormalities in brains of patients with autism report 
differences in neuronal plasticity and migration patterns rather than alterations in glial cells 
(Minshew and Williams, 2007; Minshew and Keller, 2010). Also, this cells have many 
functions that could be relevant to abnormalities described in psychiatric disorders such as 
schizophrenia (Rothermundt et al., 2004). However, the majority of studies about cellular 
mechanisms of antipsychotic drug treatment focus on neuronal effects. Therefore, a possible 
role of astrocytes has been largely neglected in ASD research.  
6. Clinical recommendations of antipsychotics in ASD 
The following clinical recommendations can be made after twenty years of clinical practice 
in Child Neurology. During this time, more than one thousand of ASD patients were seen, if 
children seen in private practice are added to those treated in our Child Neurology 
Residence Program. 
First of all, it is important to remember that until now ASD encompasses five different 
clinical diagnostic categories. These diagnostic categories will change with the new DSM-V 
classification. Even the widely used expression “ASD” may disappear. Even after the 
changes of the new classification, what is now called ASD will remain as a heterogeneous 
group both in terms of behavioral symptoms as well as in terms of medical diagnosis. 
In other words, before planning a psychopharmacological treatment in ASD, it is important 
to be sure that the diagnosis is correct. We must remember that this type of diagnosis can be 
catastrophic to parents and consequently an incorrect diagnosis would be even worse. This 
is probably one of the most important clinical recommendations. Before medications usage, 
make a double check in every diagnosis of this group of children.   
Another important remark is that each one of the five currently adopted clinical diagnostics, 
considered individually, also has its own behavioral heterogeneity, when taken 
individually. For instance, one particular case of autism may initially present as a confused 
mix of different behavioral complaints that could hide the main diagnosis. 
There is no single medication that can be successfully used in ASD as a whole. The 
guidelines recommend that monotherapy would be the best choice, but often this is difficult 
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Fig. 2. Hypothesis for the influence of Risperidone on tripartite synapse supported by its 
influence on astroglial cell culture and on hippocampal slices. After the release of glutamate 
at the synaptic cleft (1), risperidone improves glutamate uptake by astrocytes (2); stimulates 
the enzyme GS to convert glutamate into glutamine (3), which in turn is taken up by neurons 
(4), followed by resynthesis of  glutamate (5) and/or transported to the blood (6). Additionally, 
risperidone is able to stimulate the synthesis of another important fate of glutamate in 
astrocytes, the tripeptide L-glutamyl-L-cysteinyl-glycine or glutathione (GSH) (7), and to 
promote the secretion of the trophic factor S100B (8). This hypothesis was proposed 
considering the direct effect of risperidone on astroglial cells (numbers 2, 3, 7 and 8).  
or even impossible to do in the real clinical world. Although there is no ASD-specific 
medication, the psychopharmacologic treatment can decrease the “noise” surrounding 
autism, as well as facilitate the non pharmacological treatments. It is important to remember 
that the psychopharmacological approach is only one of the available treatments for ASD 
patients.  
The first clinical recommendation is to identify as clearly as possible each one of the 
behavioral symptoms. It would be extremely useful to make a list of these behavioral 
targets. After making the list, it is important try to put these targets into a ranking of clinical 
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relevance, in order to choose which one of the behavioral symptoms is more prominent 
and/or requires prompt relief. 
The second clinical recommendation is to decide if each one of the selected behavioral 
targets really will require psychopharmacological treatment. Obviously, this decision is 
somewhat more complicated and is not available in any guideline. This is the art included in 
clinical practice. The only safe way to make this decision is to use the previous experience. It 
would be helpful to discover whether a given behavioral symptom is more uncomfortable 
for parents or to the patient. For example, stereotyped and repetitive movements are 
frequently more unpleasant to parents than to the child, which can obtain a sort of relief of 
anxiety with these repetitive movements. In this case, no medication would be used. Instead 
the best recommendation would be try to find a use for the stereotyped movements.  
If the given symptom really requires psychopharmacological treatment, the third clinical 
recommendation is to choose which would be the better medication. This appears 
problematic because of the paucity of good evidence based studies with regard to the 
efficacy of medications in the treatment of autism. 
Different categories of drugs have been used to treat autism for years, despite the lack of 
proved efficacy of the majority of them. The following list of drugs that have been used in 
autism is obviously incomplete; antiepileptic drugs, mood stabilizers, antidepressants, anti-
anxiety drugs, sleep inducers, stimulants, antipsychotics, etc. 
Since there is no medication for autism itself, we must choose which of the undesirable 
behaviors could be ameliorated by antipsychotic medication. Of all of the symptoms 
presented by ASD patients, disrupted behavior and irritability probably are the best 
responders to antipsychotic drugs.  It is important to mention that many of the drugs used 
in the psychopharmacological treatment in autism, including antipsychotics, can decrease 
the seizure threshold (Tuchman, 2009). Because of ASD children are almost twenty times 
more prone to have epilepsy when compared with a child who had a normal 
neurodevelopment, probably it would be safer to consider the usefulness of an 
electroencephalogram examination before prescribing psychoactive drugs. Also, before 
prescribing antipsychotic drugs, it is useful to obtain a baseline laboratory profile, which 
includes a complete blood count, evaluation of blood lipids and glucose, liver function as 
well as prolactin levels. It is also important to measure the weight and height as well as the 
blood pressure. It is also prudent to make a complete physical and neurological 
examination. 
After prescribing antipsychotic drugs, it is necessary to monitor both the above mentioned 
measures, such as laboratorial findings as well as the clinical examination findings. In 
clinical practice, different antipsychotic drugs have been used, but only few of them still 
continue in the medical arsenal. To date, atypical antipsychotic drugs are preferred when 
compared with the typical antipsychotic drugs because of their relative safety in terms of 
side effects, especially neurologic impregnation. 
In the past, haloperidol was the typical antipsychotic more frequently used in the treatment 
of children. The daily dose usually ranges between 1 to 2 mg. The most problematic side 
effect of haloperidol seems to be neurological side effects manifested by Parkinson-like 
symptoms, extrapiramidal signs and/or tardive dyskinesia.  
Many of the available atypical antipsychotic drugs used in adult patients have also been 
used in children. The most frequently prescribed antipsychotics for ASD patients are 
risperidone, olanzapine, quetiapine, clozapina, ziprazidone and aripiprazole, however only 
two of them have been approved by the FDA for use in childhood autism. Risperidone was 
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the first atypical antipsychotic drug to be approved by the FDA, in 2006. The second drug of 
this group of medications was aripiprazole, which was approved in 2009. The usual daily 
dose of risperidone varies from 1 to 3 mg, and the usual daily dose of aripiprazole is up to 
15 mg in children and adolescents. Aripiprazole seems to be better when compared with 
risperidone in terms of side effects, because as there is a relatively lower risk of metabolic 
side effects and/or weigh gain. 
7. Conclusions and future remarks 
The first generation of antipsychotics (now called typical) has been used since the 1950s, and 
is dopamine-2 (D2) receptor antagonist. Nevertheless, the second generation, or atypical, has 
many clinical applications in neuropsychiatric practice (Schwartz and Stahl, 2011). Since the 
mid-1990’s, it is clear that atypical antipsychotics are safer in regard to inducing fewer 
extrapyramidal symptoms and tardive dyskinesia. 
At first sight, the bulk of neurochemical research in autism has been inconclusive. In 
addition, the high levels of use of many different psychotropic agents, often in combination, 
is concerning and is necessary to study the results of interactions of different types of 
medical and educational treatment for children with ASD. 
As a result of our translational research in autism, we became enthusiasts of changing the 
traditional “neuronal neuropsychiatry” approach into the modern “neuroglial 
neuropsychiatry” concept. In our opinion, the first one is somewhat simplistic because is 
totally based only on the neurons activity, and the last one is indubitably the more 
comprehensive, because there is no way to deny the importance of glial cells working 
together with neurons in the neurobiology of development and behavior, coincidentally two 
of the most altered areas in ASD patients. 
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